tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GSK Advances Share Buyback Program with Recent Purchase
Company AnnouncementsGSK Advances Share Buyback Program with Recent Purchase
2d ago
GSK Executives Sell Significant Shares on London Stock Exchange
PremiumCompany Announcements
GSK Executives Sell Significant Shares on London Stock Exchange
3d ago
FDA moves to accelerate biosimilar development, lower drug costs
PremiumThe Fly
FDA moves to accelerate biosimilar development, lower drug costs
3d ago
AZN
BMY
GSK Enhances Shareholder Value with Strategic Buyback
PremiumCompany Announcements
GSK Enhances Shareholder Value with Strategic Buyback
3d ago
GSK updates FY25 guidance with core EPS growth 10%-12%
PremiumThe Fly
GSK updates FY25 guidance with core EPS growth 10%-12%
4d ago
GSK
GSK reports Q3 core EPS 55p, up 14% at CER
PremiumThe FlyGSK reports Q3 core EPS 55p, up 14% at CER
4d ago
GSK
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Anticipated Revenue Declines and Market Challenges
Premium
Ratings
Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Anticipated Revenue Declines and Market Challenges
4d ago
GSK
Cautious Outlook on GlaxoSmithKline Despite Strong Financial Performance: Sell Rating Due to Market Headwinds and Modest Guidance Upgrades
Premium
Ratings
Cautious Outlook on GlaxoSmithKline Despite Strong Financial Performance: Sell Rating Due to Market Headwinds and Modest Guidance Upgrades
4d ago
GSK
GSK Expands Share Buyback Program with Recent Purchase
PremiumCompany Announcements
GSK Expands Share Buyback Program with Recent Purchase
4d ago
GSK Reports Strong Q3 2025 Performance and Upgrades Guidance
PremiumCompany Announcements
GSK Reports Strong Q3 2025 Performance and Upgrades Guidance
4d ago
Scynexis price target lowered to $3 from $4 at Guggenheim
PremiumThe Fly
Scynexis price target lowered to $3 from $4 at Guggenheim
5d ago
GSK
SCYX
GSK, Empirico enter license agreement for EMP-012
PremiumThe Fly
GSK, Empirico enter license agreement for EMP-012
5d ago
GSK
GSK announces GSK’227 receives Orphan Drug Designation in EU
PremiumThe FlyGSK announces GSK’227 receives Orphan Drug Designation in EU
5d ago
GSK
GSK’s GSK’227 Receives EU Orphan Drug Designation for Lung Cancer
Premium
Company Announcements
GSK’s GSK’227 Receives EU Orphan Drug Designation for Lung Cancer
5d ago
GSK Expands Share Buyback Program with Recent Purchase
Premium
Company Announcements
GSK Expands Share Buyback Program with Recent Purchase
5d ago
GSK assumed with a Buy at Jefferies
PremiumThe Fly
GSK assumed with a Buy at Jefferies
6d ago
GSK
GSK acquires exclusive rights from Syndivia for ADC in prostate cancer
PremiumThe Fly
GSK acquires exclusive rights from Syndivia for ADC in prostate cancer
6d ago
GSK
GSK Advances Share Buyback Program with Latest Purchase
PremiumCompany Announcements
GSK Advances Share Buyback Program with Latest Purchase
6d ago
Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory Hurdles
PremiumRatings
Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory Hurdles
9d ago
GSK
Sell Rating Issued for GlaxoSmithKline’s Blenrep Due to Restrictive Approval and Market Limitations
PremiumRatingsSell Rating Issued for GlaxoSmithKline’s Blenrep Due to Restrictive Approval and Market Limitations
9d ago
GSK
GSK Advances Share Buyback Program with Recent Purchase
Premium
Company Announcements
GSK Advances Share Buyback Program with Recent Purchase
9d ago
GSK’s Blenrep Gains FDA Approval for Multiple Myeloma Treatment
Premium
Company Announcements
GSK’s Blenrep Gains FDA Approval for Multiple Myeloma Treatment
9d ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >